<p>Cardiol Therapeutics Inc. (CRDL) 发布了其第三季度财报。以下是 Cardiol Therapeutics Inc. 向投资者提供的信息摘要。</p>
<h3>TipRanks 黑色星期五促销</h3>
<ul>
<li>享受 TipRanks Premium 60% 的折扣，获取您需要的数据驱动洞察和研究工具，以自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
<p>Cardiol Therapeutics Inc. 是一家临床阶段的生命科学公司，专注于开发针对心脏病的抗炎和抗纤维化疗法，其主要药物候选者 CardiolRx™ 旨在靶向炎症小体通路的激活。</p>
<p>在最新的财报中，Cardiol Therapeutics Inc. 揭示了现金储备的显著减少和持续的净亏损，反映了公司在研究和开发方面的持续投资。尽管面临财务挑战，公司仍致力于推进其临床项目。</p>
<p>报告强调，现金及现金等价物从 2024 年末的 3060 万美元减少至 2025 年 9 月 30 日的 1160 万美元。公司报告截至 2025 年 9 月 30 日的九个月内净亏损为 2660 万美元，而去年同期为 2850 万美元。运营费用有所减少，管理费用显著下降，而研发费用略有增加。</p>
<p>尽管财务亏损，Cardiol Therapeutics Inc. 继续专注于其战略举措，包括发行新股和认股权证以筹集额外资金。公司最近完成了 1140 万美元的融资，预计将支持其正在进行的临床试验和研究活动。</p>
<p>展望未来，Cardiol Therapeutics Inc. 仍然专注于推进其临床阶段项目，并探索战略机会以增强股东价值，管理层对其主要药物候选者在满足心脏病未满足医疗需求方面的潜力表示乐观。</p>

CRDL

<p>Cardiol Therapeutics Inc. 报告称，截至 2025 年 9 月 30 日的九个月内，现金储备显著减少，净亏损为 2660 万美元。尽管面临财务挑战，公司仍致力于推进其临床项目，专注于心脏病的抗炎疗法。运营费用有所减少，最近获得的 1140 万美元融资预计将支持正在进行的试验。管理层对其主要药物候选者 CardiolRx™ 保持乐观，并正在探索战略机会以提升股东价值</p>

<p>Cardiol Therapeutics Inc. ( (CRDL) ) has released its Q3 earnings. Here is a breakdown of the information Cardiol Therapeutics Inc. presented to its investors.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc. (CRDL) 发布了其第三季度财报。以下是 Cardiol Therapeutics Inc. 向投资者提供的信息摘要。</p>
</div><h3>TipRanks Black Friday Sale</h3>
<div class="lb-trans"><h3>TipRanks 黑色星期五促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 60% 的折扣，获取您需要的数据驱动洞察和研究工具，以自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
</div><p>Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate CardiolRx™ targeting inflammasome pathway activation.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc. 是一家临床阶段的生命科学公司，专注于开发针对心脏病的抗炎和抗纤维化疗法，其主要药物候选者 CardiolRx™ 旨在靶向炎症小体通路的激活。</p>
</div><p>In its latest earnings report, Cardiol Therapeutics Inc. revealed a significant decrease in cash reserves and an ongoing net loss, reflecting the company’s continued investment in research and development. The company remains committed to advancing its clinical programs despite financial challenges.</p>
<div class="lb-trans"><p>在最新的财报中，Cardiol Therapeutics Inc. 揭示了现金储备的显著减少和持续的净亏损，反映了公司在研究和开发方面的持续投资。尽管面临财务挑战，公司仍致力于推进其临床项目。</p>
</div><p>The report highlights a decrease in cash and cash equivalents from $30.6 million at the end of 2024 to $11.6 million as of September 30, 2025. The company reported a net loss of $26.6 million for the nine months ending September 30, 2025, compared to a $28.5 million loss in the same period the previous year. Operating expenses were reduced, with general and administrative costs decreasing significantly, while research and development expenses increased slightly.</p>
<div class="lb-trans"><p>报告强调，现金及现金等价物从 2024 年末的 3060 万美元减少至 2025 年 9 月 30 日的 1160 万美元。公司报告截至 2025 年 9 月 30 日的九个月内净亏损为 2660 万美元，而去年同期为 2850 万美元。运营费用有所减少，管理费用显著下降，而研发费用略有增加。</p>
</div><p>Despite the financial losses, Cardiol Therapeutics Inc. continues to focus on its strategic initiatives, including the issuance of new shares and warrants to raise additional capital. The company recently completed a US$11.4 million financing, which is expected to support its ongoing clinical trials and research activities.</p>
<div class="lb-trans"><p>尽管财务亏损，Cardiol Therapeutics Inc. 继续专注于其战略举措，包括发行新股和认股权证以筹集额外资金。公司最近完成了 1140 万美元的融资，预计将支持其正在进行的临床试验和研究活动。</p>
</div><p>Looking ahead, Cardiol Therapeutics Inc. remains focused on advancing its clinical-stage programs and exploring strategic opportunities to enhance shareholder value, with management expressing optimism about the potential of its lead drug candidate in addressing unmet medical needs in heart disease.</p>
<div class="lb-trans"><p>展望未来，Cardiol Therapeutics Inc. 仍然专注于推进其临床阶段项目，并探索战略机会以增强股东价值，管理层对其主要药物候选者在满足心脏病未满足医疗需求方面的潜力表示乐观。</p>
</div>

Cardiol Therapeutics 在临床进展的同时报告财务挑战